Bioglutidepeptide The dominant search intent for "na931 peptide" is to understand what this compound is, its mechanism of action, its therapeutic applications, and its developmental status, particularly in the context of weight managementNA-931 (Bioglutide) is a first-in-class, orally administered, small-molecule quadruple receptor agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors, .... The SERP data overwhelmingly points to NA-931 being an investigational oral medication for obesity, acting as a quadruple receptor agonist.
Tier 1:
* Core Entity: NA-931 (also known as Bioglutide™)
* Primary Action/Mechanism: Quadruple receptor agonist
* Key Targets: GLP-1, GIP, IGF-1, Glucagon
* Primary Application: Treatment of obesity, weight loss
* Key Differentiator: Oral administration
Tier 2:
* Related Compounds/Context: Tirzepatide, GLP-1 drugs
* Developmental Stage: Phase 2 clinical trials, investigational
* Company: Biomed Industries, Inc.
* Other Names: Bioglutide™
* Benefits: Weight loss, enhanced insulin secretion, reduced hypoglycemia risk, muscle mass preservation
* Administration: Oral, once-daily
* Mechanism Details: Activates four metabolic hormone receptors, small molecule
Tier 3:
* Specific dates of press releases, registration numbers, supplier information, very specific study details (unless they highlight a key differentiator), foreign language phrases that don't add significant value.
---
NA-931 peptide, also known by its developmental name Bioglutide™, is emerging as a significant advancement in the field of obesity treatment.NA-931 is at the center of the buzz. Unlike Ozempic or Mounjaro, this oral peptide pill is designed as a quadruple agonist that targets GLP This novel compound is distinguished as the first oral medication designed to act as a quadruple receptor agonist, simultaneously targeting insulin-like growth factor-1 (IGF-1), glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-agonist approach aims to offer a more comprehensive strategy for weight management compared to existing therapies, addressing multiple metabolic pathways with a single, orally administered molecule.
The core innovation behind NA-931 lies in its ability to activate four distinct metabolic hormone receptors.Trial | NCT06564753 By simultaneously engaging these pathways, NA-931 aims to mimic and enhance the body's natural regulatory processes for appetite, energy expenditure, glucose control, and fat metabolism.2189-LB: Phase 2 Clinical Trials of NA-931 to Study Subjects ...
* GLP-1 and GIP Agonism: Activation of GLP-1 and GIP receptors is well-established for promoting satiety, slowing gastric emptying, and enhancing insulin secretion in response to glucoseNA-931 (Bioglutide) is a first-in-class, orally administered, small-molecule quadruple receptor agonist targeting GLP-1, GIP, glucagon, and IGF-1 receptors, .... These actions collectively contribute to reduced food intake and improved glycemic control.
* IGF-1 and Glucagon Receptor Activation: The inclusion of IGF-1 and glucagon receptor agonism is a key differentiator for NA-931. IGF-1 plays a role in cell growth and metabolism, and its activation, alongside glucagon, may contribute to increased energy expenditure and potentially preserve muscle mass during weight loss, a common challenge with other weight-loss medications.Biomed Industries Unveils Promising Phase 2 Results of NA-931 , the ... This combination aims for effective weight reduction while mitigating some of the adverse effects often associated with GLP-1 receptor agonists.2025年6月20日—NA-931 is a quadruple agonist of the insulin-like growth hormone- (IGF-1), glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) ...
NA-931 is currently progressing through clinical trials, with Phase 2 studies underway to evaluate its safety and efficacy in adults with obesity or overweightBioglutide Explained | 4-Hormone New weight-loss Pill. These trials are designed to rigorously assess its potential for significant weight loss and its tolerability profileWhat to know about berberine, the so-called "nature's Ozempic". Early indications suggest that NA-931 may offer a compelling alternative to injectable therapies, providing the convenience of an oral pill taken once daily2025年6月20日—NA-931 is administered orally once a day for the treatment of obesity. Methods: This is a phase 2, 13-week randomized, double-blind, placebo- ....
Researchers are exploring the synergistic effects of NA-931, including its potential to be used in combination with other treatments like Tirzepatide, to further enhance efficacy and manage adverse events. The development by Biomed Industries, Inc. highlights a strategic effort to create a first-in-class oral therapy that addresses multiple facets of metabolic regulation.
The development of NA-931 represents a significant step forward, particularly due to its oral formulation. Many current effective weight-loss medications, such as those targeting GLP-1, are administered via injection. The availability of an oral peptide like NA-931 could dramatically improve patient adherence and acceptance, making advanced metabolic therapies more accessible.
Furthermore, the quadruple agonist mechanism is hypothesized to provide a more robust weight loss effect and potentially a better safety profile, including reduced risk of hypoglycemia and preservation of lean muscle mass. While still under investigation, the preclinical and early clinical data suggest NA-931 could offer a powerful new tool for individuals struggling with obesity, aiming to tackle the condition through a combination of enhanced insulin secretion, appetite suppression, and increased energy expenditure.
As NA-931 (Bioglutide™) continues through its clinical development phases, the medical community and patients alike are keenly watching its progress. The peptide's unique ability to target four key metabolic receptors via an oral route positions it as a promising candidate to redefine obesity managementBiomed Industries Presents Breakthrough Phase 2 Results .... If its efficacy and safety are confirmed in further trials, NA-931 could become a cornerstone therapy, offering a more convenient and potentially more effective solution for a widespread health challenge作者：MT Acromegaly·2025—We present phase 1 clinical trial results ofNA-931, an oral drug for the treatment of obesity. ...NA-931, a quadruple insulin-like growth factor I, glucagon- ....
Join the newsletter to receive news, updates, new products and freebies in your inbox.